Oncotelic Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanoma

NEXT STORY
Elucida Oncology Provides Corporate Update and Outlines Key Upcoming Milestones
PREV STORY
Portage Biotech Announces Participation in January 2022 Investor Conferences
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Celyad Announces the Appointment of Dr. Debasish Roychowdhury as Independent Director

MONT-SAINT-GUIBERT, Belgium, Sept. 4, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and ...

author_avatar
NASDAQ Market News

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2020

author_avatar
NASDAQ Market News

Myriad’s BRACAnalysis CDx® Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Talazoparib in Metastatic Breast Cancer

SALT LAKE CITY, June 18, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a ...

author_avatar
NASDAQ Market News